COMMUNIQUÉS West-GlobeNewswire

-
Interim report September 1, 2018 – February 28, 2019
03/04/2019 -
Dovitinib regulatory strategy confirmed and new combination biomarker DRP PD1/PD-L1 + dovitinib developed. Oncology Venture engages in partnering activities with Destum Partners
03/04/2019 -
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
03/04/2019 -
Santhera Provides Update on Near-term Corporate Financing Initiatives
03/04/2019 -
ADMA Receives Department of Health and Human Services U.S. License
03/04/2019 -
Ken Ludlum Appointed to IRIDEX Board of Directors
03/04/2019 -
Veloxis Increases Share Capital in Connection with Exercise of Warrants
02/04/2019 -
BODY GLOBE BODY ARMOR® COMPLETES LEVEL II BALLISTICS TEST HOVERINK BIOTECHNOLOGIES ANNOUNCES THEY ARE NOW TAKING PRE-SALE ORDERS
02/04/2019 -
MacroGenics to Participate in Upcoming Investor Conferences
02/04/2019 -
Corium Appoints Perry Sternberg as Chief Executive Officer
02/04/2019 -
Natus Announces Sale of Medix Business
02/04/2019 -
Geron to Present at Needham Healthcare Conference
02/04/2019 -
Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
02/04/2019 -
Clearside Biomedical to Present at the 18th Annual Needham Healthcare Conference
02/04/2019 -
Dova Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
02/04/2019 -
Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
02/04/2019 -
Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
02/04/2019 -
Agios Announces New Commercial Leadership Structure
02/04/2019 -
Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE™ Significantly Outperforms Current Prediction Methods
02/04/2019
Pages